A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

Inclusion Criteria:

• Participants must have a diagnosis of CD or fistulizing CD, with active colitis,ileitis, or ileocolitis, confirmed at any time in the past by clinical, endoscopic,and histologic criteria.

• Participants have moderately to severely active CD (as defined by a baseline PCDAIscore ≥30).

• Participants must have endoscopy with evidence of active CD defined as SES-CD score ≥6 (or ≥4 for participants with isolated ileal disease) within 1 month of receivingstudy intervention at Week 0.

• Participants must have a documented history of inadequate response, loss of responseor intolerance to at least one medication used to treat CD, which may includeimmunomodulators, oral or IV corticosteroids, a biologic therapy or a JAK inhibitor.

Exclusion Criteria:

• Participants must not have complications of CD such as symptomatic strictures orstenosis, short gut syndrome, or any other manifestations that might be anticipatedto require surgery.

• Participants must not have an abscess.

• Participants must not have any kind of bowel resection within 26 weeks or any otherintra-abdominal surgery within 12 weeks of baseline.